SAFINAMIDE メシル酸塩
SAFINAMIDE メシル酸塩 物理性質
- 融点 :
- 210° (dec)
- 比旋光度 :
- D25 +12.9° (c = 1.1% in 98% acetic acid)
- 貯蔵温度 :
- 2-8°C
- 溶解性:
- H2O: ≥15mg/mL
- 外見 :
- 粉
- 色:
- 白から黄褐色
- 光学活性 (optical activity):
- [α]/D +9.5 to +14°, c = 1 (95% acetic acid)
SAFINAMIDE メシル酸塩 価格
もっと(3)
| メーカー |
製品番号 |
製品説明 |
CAS番号 |
包装 |
価格 |
更新時間 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
W01MAS093786 |
(S)-2-((4-((3-Fluorobenzyl)oxy)benzyl)-amino)propanamide methanesulfonate |
202825-46-5 |
250mg |
￥2608200 |
2024-03-01 |
購入 |
|
Sigma-Aldrich Japan
|
SML0025 |
Safinamide メシル酸塩 ≥98% (HPLC)
Safinamide mesylate salt ≥98% (HPLC) |
202825-46-5 |
5mg |
￥20600 |
2024-03-01 |
購入 |
|
Sigma-Aldrich Japan
|
SML0025 |
Safinamide メシル酸塩 ≥98% (HPLC)
Safinamide mesylate salt ≥98% (HPLC) |
202825-46-5 |
25mg |
￥125000 |
2024-03-01 |
購入 |
SAFINAMIDE メシル酸塩 化学特性,用途語,生産方法
効能
パーキンソン病治療薬, モノアミン酸化酵素B(MAO-B)阻害薬
説明
Safinamide
methanesulfonate was approved in February 2015 by the
EMA for the treatment of mid- to late-stage fluctuating
Parkinson’s disease. This approval included use of the drug as
an add-on therapy for use with levodopa, either alone or in
combination with other existing therapies for Parkinson’s
disease.51 Safinamide methanesulfonate, an oral α-aminoamide
originally discovered by Farmitalia Carlo Erba and later
developed by Newron/Zambon, functions as a highly selective
and reversible inhibitor of MAO-B, leading to increased levels
of dopamine and subsequent improvement in the motor
symptoms of Parkinson’s disease, side effects that often result
from use of other traditional treatments relying on dopamine
replacement therapy.
使用
Safinamide mesylate salt has been used as a reference drug to study its inhibitory effect on human monoamine oxidases (hMAO-A and hMAO-B).
作用機序
Safinamide employs several mechanisms of action, functioning
as both a dopaminergic agent through inhibition of MAO-B as
well as a nondopaminergic agent via selective calcium and
sodium channel modulation, leading to inhibition of glutamate
release. At least one of several clinical studies of patients
with mid- to late-stage Parkinson’s disease showed increased
daily ON time (periods of symptom control) without
accompanying motor complications (dyskinesias) upon treatment
with safinamide, while studies of early stage Parkinson’s
disease patients treated with this drug showed significantly
improved motor symptoms during the 18-month study.
Additionally, safinamide is chemically and metabolically
stable, is well tolerated in patients, and has not exhibited
serious adverse effects even upon treatment at higher dosage
ranges.
副作用
Common adverse events in clinical trials (in more than 1% of people) included nausea, dizziness, tiredness, sleeplessness, or thostatic hypotension (low blood pressure) and headache. There was no significant difference in the occurrence of these effects between safinamide and placebo.
SAFINAMIDE メシル酸塩 上流と下流の製品情報
原材料
準備製品
SAFINAMIDE メシル酸塩 生産企業
Global( 236)Suppliers
SAFINAMIDE メシル酸塩 スペクトルデータ(1HNMR)
202825-46-5(SAFINAMIDE メシル酸塩)キーワード:
- 202825-46-5
- (S)-2-[[4-[(3-Fluorobenzyl)oxy]benzyl]amino]propanamide methanesulfonate
- Safinamide mesylate
- EMD 1195686 Mesylate
- NW 1015
- PNU 151774E
- SafinaMide Methanesulfonate
- PNU-151774E,FCE28073
- (S)-(+)-2-[[4-(3-Fluorobenzoxy)benzyl]amino]propanamide
- PNU-151774E, NW-1015
- Safinamide mesylate salt
- SafinaMide Mesylate(FCE28073)
- Safinamide mesylate, >=99%
- 2(S)-[4-(3-Fluorobenzyloxy)benzylamino]propionamide methanesulfonate
- Safinamide Mesyalte
- Propanamide, 2-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino]-, (2S)-, methanesulfonate (1:1)
- Safinamidemesylatesal
- Safinamide mesylate USP/EP/BP
- 2(S)-[4-(3-Fluorobenzyloxy)benzylamino]propionamide methanes...
- Salfenamide mesulfonate
- Safinamide Mesilate
- Propanamide,2-[[[4-[(3-fluorophenyl)methoxy]- phenyl]methyl]amino]-,(2S)-,monomethanesulfonate
- S819080 Safinamide Mesylate
- Haloxyfop Impurity 8 ((R)-Clodinafop)
- Salfenamide mesylate
- Safinamtde Mesytate
- SAFINAMIDE メシル酸塩
- サフィナミドメシル酸塩
- サフィナミドメシル酸塩 (JAN)